Wellington Management Group LLP Boosts Position in Omnicell, Inc. $OMCL

Key Points

• Wellington Management Group LLP increased its stake in Omnicell, Inc. by 52.6% during the first quarter, owning approximately 1.06% of the company, with total shares amounting to 496,680.
• Omnicell reported earnings of $0.45 per share for the latest quarter, surpassing the consensus estimate of $0.30, and recorded revenues of $290.56 million, which were above expectations.
• Analysts have mixed ratings on Omnicell, with a consensus price target of $46.71, as four analysts rated it a "Buy" and three a "Hold".

Wellington Management Group LLP boosted its holdings in Omnicell, Inc. (NASDAQ:OMCL - Free Report) by 52.6% during the first quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund owned 496,680 shares of the company's stock after acquiring an additional 171,116 shares during the period. Wellington Management Group LLP owned 1.06% of Omnicell worth $17,364,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other large investors have also recently added to or reduced their stakes in OMCL. Lazard Asset Management LLC boosted its stake in shares of Omnicell by 81.6% during the 4th quarter. Lazard Asset Management LLC now owns 1,641,817 shares of the company's stock worth $73,093,000 after purchasing an additional 737,536 shares during the last quarter. Toronto Dominion Bank acquired a new stake in shares of Omnicell during the 4th quarter worth about $30,637,000. Dimensional Fund Advisors LP boosted its stake in shares of Omnicell by 31.6% during the 4th quarter. Dimensional Fund Advisors LP now owns 1,642,626 shares of the company's stock worth $73,127,000 after purchasing an additional 394,820 shares during the last quarter. Pacer Advisors Inc. acquired a new stake in shares of Omnicell during the 1st quarter worth about $10,542,000. Finally, Nuveen LLC acquired a new stake in shares of Omnicell during the 1st quarter worth about $6,218,000. 97.70% of the stock is owned by institutional investors and hedge funds.

Omnicell Trading Down 2.1%

Shares of OMCL stock traded down $0.69 during trading hours on Friday, hitting $32.59. 595,171 shares of the company were exchanged, compared to its average volume of 577,128. The firm has a market cap of $1.50 billion, a PE ratio of 65.18, a PEG ratio of 7.27 and a beta of 0.78. Omnicell, Inc. has a 1 year low of $22.66 and a 1 year high of $55.74. The company has a quick ratio of 1.24, a current ratio of 1.42 and a debt-to-equity ratio of 0.13. The firm has a fifty day moving average of $30.07 and a 200 day moving average of $31.62.

Omnicell (NASDAQ:OMCL - Get Free Report) last announced its quarterly earnings data on Thursday, July 31st. The company reported $0.45 earnings per share for the quarter, topping the consensus estimate of $0.30 by $0.15. The business had revenue of $290.56 million for the quarter, compared to analyst estimates of $275.57 million. Omnicell had a net margin of 2.01% and a return on equity of 4.27%. The company's revenue was up 5.0% on a year-over-year basis. During the same period in the prior year, the firm posted $0.51 EPS. Omnicell has set its FY 2025 guidance at 1.400-1.650 EPS. Q3 2025 guidance at 0.300-0.370 EPS. Analysts expect that Omnicell, Inc. will post 1.09 earnings per share for the current year.

Analyst Upgrades and Downgrades

OMCL has been the topic of several analyst reports. Wall Street Zen cut shares of Omnicell from a "strong-buy" rating to a "buy" rating in a research note on Saturday, August 9th. Piper Sandler decreased their price target on shares of Omnicell from $57.00 to $55.00 and set an "overweight" rating on the stock in a research note on Monday, August 11th. Wells Fargo & Company raised their price target on shares of Omnicell from $37.00 to $40.00 and gave the stock an "overweight" rating in a research note on Monday, July 21st. Bank of America raised their price target on shares of Omnicell from $30.00 to $34.00 and gave the stock a "neutral" rating in a research note on Friday, May 23rd. Finally, Benchmark decreased their price target on shares of Omnicell from $62.00 to $40.00 and set a "buy" rating on the stock in a research note on Wednesday, May 7th. Four equities research analysts have rated the stock with a Buy rating and three have issued a Hold rating to the company. According to data from MarketBeat.com, Omnicell currently has a consensus rating of "Moderate Buy" and an average price target of $46.71.

Omnicell Profile

Omnicell, Inc, together with its subsidiaries, provides medication management solutions and adherence tools for healthcare systems and pharmacies the United States and internationally. The company offers point of care automation solutions to improve clinician workflows in patient care areas of the healthcare system; XT Series automated dispensing systems for medications and supplies used in nursing units and other clinical areas of the hospital, as well as specialized automated dispensing systems for operating room; and robotic dispensing systems for handling the stocking and retrieval of boxed medications.